Trials / Completed
CompletedNCT01903720
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 71 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | dexamethasone implant | OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months. |
Timeline
- Start date
- 2013-07-16
- Primary completion
- 2014-09-24
- Completion
- 2015-03-30
- First posted
- 2013-07-19
- Last updated
- 2019-04-17
- Results posted
- 2016-07-21
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01903720. Inclusion in this directory is not an endorsement.